News & Events – Sumitovant

Select Company

May 20, 2021Altavant Sciences Reports Rodatristat Ethyl PK/PD Analysis at ATS Supporting Doses Selected for Phase 2b ELEVATE 2 Study
May 06, 2021Altavant Sciences Advances Rodatristat Ethyl into Phase 2b Clinical Trial for Pulmonary Arterial Hypertension
April 26, 2021Altavant Sciences Finds Nebulized ALTA-2530 Retains Potency and Reaches Target Lung Tissues, Supporting Continued Investigation for Treatment of BOS
April 21, 2021Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting
February 18, 2021Altavant Sciences Initiates Chemical Lung Injury Program in Collaboration with the BARDA and NIAID
August 05, 2020Altavant Sciences Presentation at ATS 2020 Confirms Minimal Brain Exposure of Peripherally Acting Serotonin Modulator, Rodatristat Ethyl, in Clinical Development for PAH
May 02, 2020Altavant Sciences Appoints Respiratory Disease Medical Expert as Chief Medical Officer
March 02, 2020Altavant Sciences Appoints Respiratory Disease Medical Expert as Chief Medical Officer
January 08, 2020Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline
October 22, 2019Altavant Sciences Presents Data at CHEST 2019 Supporting Once-Daily Dosing of Rodatristat Ethyl for the Treatment of Pulmonary Arterial Hypertension
1 2 Next »